Area of research
Genetics · Pharmacology
Research interest
Research interests include Breast cancer, Tamoxifen, Medicine, Oncology, Internal medicine, and CYP2D6.
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer
Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort
Cross‐Ancestry Genome‐Wide Association Study Defines the Extended <scp><i>CYP2D6</i></scp> Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
mitoBKCa is functionally expressed in murine and human breast cancer cells and potentially contributes to metabolic reprogramming
(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients
Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1
The Influences of Adherence to Tamoxifen and <i>CYP2D6</i> Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
Abstract 3425: Exome-sequencing derived mutations of endocrine treated ER-positive early breast cancer
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
SK4 channels modulate Ca<sup>2+</sup> signalling and cell cycle progression in murine breast cancer
Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods
The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
Abstract 5033: Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
Abstract 2030: The role of genetic variation in calcium-activated potassium channels in breast cancer patients treated with tamoxifen
Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype
Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS
Abstract 5485: Coactivator PPARGC1B Ala203Pro polymorphism is linked with estrogen-related receptor function and breast cancer outcome
Abstract 5483: CYP19A1 genetic variation is a potential predictor of outcome in ER-positive postmenopausal early breast cancer patients treated with tamoxifen
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations